Have a feature idea you'd love to see implemented?
Let us know!
TNXP Tonix Pharmaceuticals Holding Corp
Price (delayed)
$0.1605
Market cap
$3.53M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$66
Enterprise value
$8.63M
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix's
Highlights
TNXP's EPS has soared by 80% YoY and by 31% from the previous quarter
The company's revenue rose by 22% QoQ
TNXP's quick ratio has plunged by 76% YoY
The company's equity has shrunk by 70% YoY and by 61% QoQ
Key stats
What are the main financial stats of TNXP
Market
Valuations
Earnings
Shares outstanding
22M
Market cap
$3.53M
Enterprise value
$8.63M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.01
Price to sales (P/S)
0.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.69
Revenue
$12.46M
EBIT
-$149.01M
EBITDA
-$144.12M
Free cash flow
-$74.58M
Per share
Balance sheet
Liquidity
EPS
-$66
Free cash flow per share
-$18.26
Book value per share
$14.1
Revenue per share
$3.05
TBVPS
$17.18
Total assets
$70.31M
Total liabilities
$28.2M
Debt
$9.26M
Equity
$42.1M
Working capital
$3.24M
Debt to equity
0.22
Current ratio
1.15
Quick ratio
0.34
Net debt/EBITDA
-0.04
Margins
Efficiency
Dividend
EBITDA margin
-1,156.8%
Gross margin
21.6%
Net margin
-1,196.1%
Operating margin
-1,237.3%
Return on assets
-119.4%
Return on equity
-158.3%
Return on invested capital
-159%
Return on capital employed
-308.7%
Return on sales
-1,196.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TNXP stock price
How has the Tonix Pharmaceuticals Holding stock price performed over time
Intraday
-4.46%
1 week
-10.54%
1 month
23.46%
1 year
-99.07%
YTD
-98.76%
QTD
8.08%
Financial performance
How have Tonix Pharmaceuticals Holding's revenue and profit performed over time
Revenue
$12.46M
Gross profit
$2.69M
Operating income
-$154.14M
Net income
-$149.01M
Gross margin
21.6%
Net margin
-1,196.1%
The net income has dropped by 51% since the previous quarter and by 22% year-on-year
Tonix Pharmaceuticals Holding's operating income has decreased by 46% from the previous quarter and by 23% YoY
TNXP's gross margin is down by 43% from the previous quarter
The gross profit has contracted by 30% from the previous quarter
Growth
What is Tonix Pharmaceuticals Holding's growth rate over time
Valuation
What is Tonix Pharmaceuticals Holding stock price valuation
P/E
N/A
P/B
0.01
P/S
0.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.69
TNXP's EPS has soared by 80% YoY and by 31% from the previous quarter
The P/B is 99% lower than the 5-year quarterly average of 0.7 and 90% lower than the last 4 quarters average of 0.1
The company's equity has shrunk by 70% YoY and by 61% QoQ
TNXP's P/S is 96% below its last 4 quarters average of 1.2
The company's revenue rose by 22% QoQ
Efficiency
How efficient is Tonix Pharmaceuticals Holding business performance
The company's return on equity has shrunk by 136% YoY and by 91% QoQ
TNXP's ROA has shrunk by 94% YoY and by 78% QoQ
TNXP's return on invested capital has dropped by 72% since the previous quarter and by 23% year-on-year
TNXP's ROS is down by 24% from the previous quarter
Dividends
What is TNXP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TNXP.
Financial health
How did Tonix Pharmaceuticals Holding financials performed over time
The total assets is 149% more than the total liabilities
TNXP's quick ratio has plunged by 76% YoY
The current ratio has dropped by 59% year-on-year and by 22% since the previous quarter
The debt is 78% smaller than the equity
The debt to equity has soared by 144% from the previous quarter
The company's equity has shrunk by 70% YoY and by 61% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.